{
    "Trade/Device Name(s)": [
        "Elecsys proBNP Immunoassay",
        "proBNP test"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K051382",
    "Predicate Device Reference 510(k) Number(s)": [
        "K032646",
        "K022516"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "October 14, 2005",
    "Summary Letter Received Date": "October 17, 2005",
    "Submission Date": "November 28, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-type natriuretic peptide test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac",
        "misc"
    ],
    "Analyte(s)": [
        "N-terminal proBrain Natriuretic Peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Elecsys 1010",
        "Elecsys 2010",
        "MODULAR analytics E170"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescent Immunoassay (ECLIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys proBNP Immunoassay for quantitative measurement of NT-proBNP in serum and plasma on Roche Elecsys analyzers",
    "Indications for Use Summary": "Aids in diagnosis of suspected congestive heart failure, risk stratification of patients with acute coronary syndrome or congestive heart failure, and assessment of increased cardiovascular risk in patients with stable coronary artery disease",
    "fda_folder": "Clinical Chemistry"
}